Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (27)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kari, J. A.
Right arrow Articles by Dillon, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kari, J. A.
Right arrow Articles by Dillon, M. J.
Related Collections
Right arrow Osteoarthritis and Cartilage
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 933-938
© 2001 British Society for Rheumatology

Paediatric Rheumatology

Behçet's disease in UK children: clinical features and treatment including thalidomide

Paediatric Rheumatology/Series Editor: P. Woo

J. A. Kari, V. Shah and M. J. Dillon

Nephrourology Unit, Great Ormond St NHS Trust, London, UK

Abstract

Objective. To study the clinical spectrum of Behçet's disease (BD) in childhood, and to report our experience of using thalidomide.

Method. Ten children, diagnosed with BD, were studied retrospectively.

Results. The median (range) age at first presentation was 4 (1.2–12.0) yr, at diagnosis was 11 (3–15) yr and the follow-up period was 4.1 (0.6–6.3) yr. Oral ulcers were present in all patients (100%), genital ulcers were present in six (60%), peri-anal ulcers were present in three (30%), skin manifestations were present in nine (90%), intracranial hypertension was present in two (20%), mild gastrointestinal symptoms were present in five (50%), joint symptoms were present in six (60%), ocular lesions were present in five (50%), but only one child had anterior and posterior uveitis. Therapeutically, a range of drugs was used, including colchicine, that resulted in good responses in five children. Thalidomide (1 mg/kg/week to 1 mg/kg/day) was used in five children who were unresponsive to other immunosuppressive agents. It resulted in complete remission in three children and less frequent milder oral ulcers in two. Neuropathy developed in two children and in one it was irreversible.

Conclusion. BD in children is similar to the disease in adults. Thalidomide provided a useful therapeutic option for severe oral and genital ulceration which was unresponsive to other therapies. Awareness of the danger of axonal neuropathy and teratogenesis at all times during thalidomide therapy is crucial. A low dose is probably as effective as higher doses.

KEY WORDS: Behçet's disease, Children, Thalidomide.

Notes

Correspondence to: J. A. Kari, PO Box 13042, Jeddah 21943, Saudi Arabia.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Dent. Res.Home page
L.M. Al-Otaibi, S.R. Porter, and T.W.J. Poate
Behcet's Disease: A Review
J. Dent. Res., March 1, 2005; 84(3): 209 - 222.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
J. F. Schoeman, P. Springer, A. J. van Rensburg, S. Swanevelder, W. A. Hanekom, P. A. J. Haslett, and G. Kaplan
Adjunctive Thalidomide Therapy for Childhood Tuberculous Meningitis: Results of a Randomized Study
J Child Neurol, April 1, 2004; 19(4): 250 - 257.
[Abstract] [PDF]

Home page
 BloodHome page
R. LeBlanc, T. Hideshima, L. P. Catley, R. Shringarpure, R. Burger, N. Mitsiades, C. Mitsiades, P. Cheema, D. Chauhan, P. G. Richardson, et al.
Immunomodulatory drug costimulates T cells via the B7-CD28 pathway
Blood, March 1, 2004; 103(5): 1787 - 1790.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.